260,633 Shares in IQVIA Holdings Inc. (NYSE:IQV) Acquired by Criteria Caixa S.A.U.

Criteria Caixa S.A.U. acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 260,633 shares of the medical research company's stock, valued at approximately $51,217,000. IQVIA comprises about 7.3% of Criteria Caixa S.A.U.'s investment portfolio, making the stock its 5th biggest holding. Criteria Caixa S.A.U. owned about 0.14% of IQVIA at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Norges Bank bought a new stake in shares of IQVIA during the 4th quarter worth about $336,041,000. Raymond James Financial Inc. bought a new stake in shares of IQVIA during the 4th quarter worth about $236,120,000. American Century Companies Inc. raised its position in shares of IQVIA by 396.0% during the 4th quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company's stock worth $222,987,000 after buying an additional 905,960 shares in the last quarter. Invesco Ltd. raised its position in shares of IQVIA by 53.4% during the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock worth $509,012,000 after buying an additional 902,226 shares in the last quarter. Finally, Canada Pension Plan Investment Board grew its stake in shares of IQVIA by 20.0% in the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock worth $841,461,000 after purchasing an additional 712,958 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Price Performance

IQV traded up $1.65 during midday trading on Wednesday, reaching $155.10. 2,232,397 shares of the company's stock were exchanged, compared to its average volume of 1,431,923. The firm has a market capitalization of $27.35 billion, a price-to-earnings ratio of 20.68, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a one year low of $135.97 and a one year high of $252.88. The business has a 50-day simple moving average of $169.86 and a two-hundred day simple moving average of $192.72.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

IQV has been the topic of several recent research reports. UBS Group lowered their price objective on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Royal Bank of Canada reissued an "outperform" rating and issued a $270.00 target price on shares of IQVIA in a research report on Monday, February 10th. BTIG Research cut shares of IQVIA from a "buy" rating to a "neutral" rating in a report on Monday, February 3rd. Mizuho decreased their price target on shares of IQVIA from $242.00 to $210.00 and set an "outperform" rating for the company in a report on Wednesday, April 9th. Finally, Morgan Stanley raised their price target on shares of IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Eight research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $237.62.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.